ShiveringPhase 4NCT05110469
Comparison of MgSO4 Versus Meperidine for Prevention of Shivering During Spinal Anesthesia
A Phase 4 study testing Magnesium sulfate and Meperidine in people with Shivering, run by AnestesiaR at 1 site in Indonesia.
Trial summary
This was a double-blind randomized interventional study of 100 patients divided into two groups. Group M received MgSO4 30 mg/kg, and group P received meperidine 0.5 mg/kg intravenously in 100 ml of 0.9% NaCl before undergoing spinal anesthesia. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Shivering
- What is being tested?
- Magnesium sulfate and Meperidine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteIndonesia
- Study dates
- 1 Feb 2021to 30 Jun 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Aged 18-65 years old
- American Society of Anesthesiologist (ASA) physical status I or II
- Planning for spinal anesthesia
Who cannot join
- History of allergy to the drugs used in the study
- Pregnant patients
- With neuromuscular disease, hyperthyroid, severe cardiopulmonary diseases, liver and/or renal disorders
- Used drugs that could interact with MgSO4 such as nifedipine
- Preoperative body temperature less than 36oC or more than 37.5oC
Trial locations and contacts
1 site in 1 country.
Indonesia1 site
Dr. Cipto Mangunkusumo National General Hospital
Jakarta, DKI Jakarta, 10430
About this study
Official title: The Comparison of Intravenous Magnesium Sulphate and Intravenous Meperidine for Prevention of Shivering During Spinal Anesthesia
This was a double-blind randomized interventional study of 100 patients divided into two groups. Group M received MgSO4 30 mg/kg, and group P received meperidine 0.5 mg/kg intravenously in 100 ml of 0.9% NaCl before undergoing spinal anesthesia. Participants were non-pregnant patients between 18-65 years of age, belonging to the American Society of Anesthesiologist physical status I or II. Shivering was regarded as significant if it occurred at grade 3 or 4. Data of patient characteristics, shivering degree, tympanic membrane temperature, vital sign, and side effects were recorded.
Read the detailed description
Study Design This was double-blinded randomized clinical trial that was conducted in Dr. Cipto Mangunkusumo National General Hospital in February - June 2021 after due permission from Ethics Committee of the Faculty of Medicine University of Indonesia - Cipto Mangunkusumo Hospital (No. KET-1510/UN2.F1/ETIK/PPM.00.02/2020). Patients were randomly devided into two groups to recieved MgSO4 30 mg/kg (group M) and meperidine 0.5 mg/kg (group P). Drugs will be prepared and delivered by another anesthesiologist outside of the research team.
Subjects Following patient informed consent, 100 patients aged 18-65 years old, with American Society of Anesthesiologist (ASA) physical status I or II who underwent spinal anesthesia. The following groups of patients were excluded from the study: patients with a history of allergy to the drugs used in the study, pregnant patients, neuromuscular disease, hyperthyroid, severe cardiopulmonary diseases, liver and/or renal disorders, used drugs that could interact with MgSO4 such as nifedipine, and preoperative body temperature less than 36oC or more than 37.5oC. Patients were dropped out if: any complications such as systemic allergic reaction, anaphylaxis, cardiac arrest was occured, failure of spinal anesthesia, respinal, surgery duration less than 30 minutes, and conversion to general anesthesia during evaluation.
Interventions and Outcomes After randomization, subjects would be given drugs according to their randomization group. MgSO4 30 mg/kg and meperidine 0.5 mg/kg were dissolved in 100 ml NaCl 0.9%, and labeled as "research drug" for blinding. Drugs were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression. If hypotension occurs or blood pressure decreases >20% from baseline, patients will be treated with a crystalloid solution and intravenous ephedrine 5-10 mg.
Afterwards, patients were given 10 ml/kg crystalloid with room temperature 22oC - 23oC for 10 minutes before spinal anesthesia. Spinal anesthesia was performed at the lumbar vertebrae 3-4 or 4-5 interspaces, with 15 mg hyperbaric bupivacaine and fentanyl 25 mcg. Room temperature was maintained between 19oC - 24oC. Patients were covered with one layer of blanket, which covered the chest and upper arm, and other areas outside the operating area. Patients were given fluid maintenance of 2 ml/kg/hour crystalloid and oxygen supplementation 2-3 l/minute by nasal cannula. Patient ini this study also were managed in the state of Ramsay sedation scale 2 (co-operative, oriented, and tranquil) or 3 (appears asleep, but responds to verbal command), so some patient were given midazolam intravenously to maintain the condition.
The incidence of shivering, mean arterial pressure, heart rate, respiratory rate, and tympanic membrane temperature were observed every five minutes during the first 15 minutes and every 15 minutes within the next 120 minutes. The degree of shivering was measured with Crossley and Mahajan scale which is 0 = No shivering, 1 = piloerection or peripheral vasoconstriction, 2 = muscular activity in only 1 muscle group, 3 = muscular activity in more than 1 muscle group but not generalized, and 4 = intens shivering involving the whole body, except in the muscle affected by spinal block.6 Drugs were considered effective if they could prevent the incidence of 3rd or 4th degree shivering. Meperidine 25 mg intravenously was given if 3rd or 4th degree shivering occurred. Nausea and vomiting was treated by IV metoclopramide 10 mg. Postoperatively, all patients were transferred to recovery room and monitored for one hour until discharge.
Statistical Analysis All statistical analyses were performed using SPSS (Statistical Package for Social Sciences) version 20.0. Chi-square test or Fisher's exact test were used to compare the difference of proportion in shivering between the two groups. For numerical data, T-test and Mann-Whitney test were used. P<0.05 was considered statistically significant.
- Conditions
- Shivering
- Being tested
- Magnesium sulfate, Meperidine
- Keywords
- Magnesium sulphate, meperidine, shivering, spinal anesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium sulfateDrug
IV Magnesium sulphate 30 mg/kg, labeled as "research drug" for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression.
MeperidineDrug
IV Meperidine 0.5 mg/kg, labeled as "research drug" for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression.
| Study group | Role | What they receive |
|---|---|---|
| Group M | Experimental | IV Magnesium sulphate 30 mg/kg in 100 ml NaCl 0.9% Receives: Drug: Magnesium sulfate |
| Group P | Experimental | IV Meperidine 0.5 mg/kg in 100 ml NaCl 0.9% Receives: Drug: Meperidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Drug effectiveness
Drugs were considered effective if they could prevent the incidence of 3rd or 4th degree shivering
Measured: 120 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2021
- Study start1 Feb 2021
- Primary completion30 Jun 2021
- Study completion30 Jun 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ShiveringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Non-pregnant patients between 18-65 years of age, belonging to the American Society of Anesthesiologist physical status I or II who underwent spinal anesthesia.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- AnestesiaR
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Magdalena Sihombing, AnestesiaR
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05110469
- Sponsor's protocol ID
- MagnesiumAS01
- Status last verified
- Oct 2021
- First submitted
- 14 Oct 2021
- Last updated
- 8 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Comparison of Intravenous Magnesium Sulphate and Intravenous Meperidine for Prevention of Shivering During Spinal Anesthesia
- ClinicalTrials.gov ID
- NCT05110469
- Acronym / sponsor ID
- MagnesiumAS01
- Conditions
- Shivering
- Keywords
- Magnesium sulphate, meperidine, shivering, spinal anesthesia
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- AnestesiaRUniversity, hospital or other
- Study start
- 1 Feb 2021 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 30 Jun 2021 (actual)
- First posted
- 8 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This was a double-blind randomized interventional study of 100 patients divided into two groups. Group M received MgSO4 30 mg/kg, and group P received meperidine 0.5 mg/kg intravenously in 100 ml of 0.9% NaCl before undergoing spinal anesthesia. Participants were non-pregnant patients between 18-65 years of age, belonging to the American Society of Anesthesiologist physical status I or II. Shivering was regarded as significant if it occurred at grade 3 or 4. Data of patient characteristics, shivering degree, tympanic membrane temperature, vital sign, and side effects were recorded.
Detailed description
Study Design This was double-blinded randomized clinical trial that was conducted in Dr. Cipto Mangunkusumo National General Hospital in February - June 2021 after due permission from Ethics Committee of the Faculty of Medicine University of Indonesia - Cipto Mangunkusumo Hospital (No. KET-1510/UN2.F1/ETIK/PPM.00.02/2020). Patients were randomly devided into two groups to recieved MgSO4 30 mg/kg (group M) and meperidine 0.5 mg/kg (group P). Drugs will be prepared and delivered by another anesthesiologist outside of the research team.
Subjects Following patient informed consent, 100 patients aged 18-65 years old, with American Society of Anesthesiologist (ASA) physical status I or II who underwent spinal anesthesia. The following groups of patients were excluded from the study: patients with a history of allergy to the drugs used in the study, pregnant patients, neuromuscular disease, hyperthyroid, severe cardiopulmonary diseases, liver and/or renal disorders, used drugs that could interact with MgSO4 such as nifedipine, and preoperative body temperature less than 36oC or more than 37.5oC. Patients were dropped out if: any complications such as systemic allergic reaction, anaphylaxis, cardiac arrest was occured, failure of spinal anesthesia, respinal, surgery duration less than 30 minutes, and conversion to general anesthesia during evaluation.
Interventions and Outcomes After randomization, subjects would be given drugs according to their randomization group. MgSO4 30 mg/kg and meperidine 0.5 mg/kg were dissolved in 100 ml NaCl 0.9%, and labeled as "research drug" for blinding. Drugs were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression. If hypotension occurs or blood pressure decreases >20% from baseline, patients will be treated with a crystalloid solution and intravenous ephedrine 5-10 mg.
Afterwards, patients were given 10 ml/kg crystalloid with room temperature 22oC - 23oC for 10 minutes before spinal anesthesia. Spinal anesthesia was performed at the lumbar vertebrae 3-4 or 4-5 interspaces, with 15 mg hyperbaric bupivacaine and fentanyl 25 mcg. Room temperature was maintained between 19oC - 24oC. Patients were covered with one layer of blanket, which covered the chest and upper arm, and other areas outside the operating area. Patients were given fluid maintenance of 2 ml/kg/hour crystalloid and oxygen supplementation 2-3 l/minute by nasal cannula. Patient ini this study also were managed in the state of Ramsay sedation scale 2 (co-operative, oriented, and tranquil) or 3 (appears asleep, but responds to verbal command), so some patient were given midazolam intravenously to maintain the condition.
The incidence of shivering, mean arterial pressure, heart rate, respiratory rate, and tympanic membrane temperature were observed every five minutes during the first 15 minutes and every 15 minutes within the next 120 minutes. The degree of shivering was measured with Crossley and Mahajan scale which is 0 = No shivering, 1 = piloerection or peripheral vasoconstriction, 2 = muscular activity in only 1 muscle group, 3 = muscular activity in more than 1 muscle group but not generalized, and 4 = intens shivering involving the whole body, except in the muscle affected by spinal block.6 Drugs were considered effective if they could prevent the incidence of 3rd or 4th degree shivering. Meperidine 25 mg intravenously was given if 3rd or 4th degree shivering occurred. Nausea and vomiting was treated by IV metoclopramide 10 mg. Postoperatively, all patients were transferred to recovery room and monitored for one hour until discharge.
Statistical Analysis All statistical analyses were performed using SPSS (Statistical Package for Social Sciences) version 20.0. Chi-square test or Fisher's exact test were used to compare the difference of proportion in shivering between the two groups. For numerical data, T-test and Mann-Whitney test were used. P<0.05 was considered statistically significant.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Non-pregnant patients between 18-65 years of age, belonging to the American Society of Anesthesiologist physical status I or II who underwent spinal anesthesia.
| Arm | Type | Receives |
|---|---|---|
| Group M | Experimental | Drug: Magnesium sulfateIV Magnesium sulphate 30 mg/kg in 100 ml NaCl 0.9% |
| Group P | Experimental | Drug: MeperidineIV Meperidine 0.5 mg/kg in 100 ml NaCl 0.9% |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Aged 18-65 years old
- American Society of Anesthesiologist (ASA) physical status I or II
- Planning for spinal anesthesia
Key exclusion criteria (5 listed)
- History of allergy to the drugs used in the study
- Pregnant patients
- With neuromuscular disease, hyperthyroid, severe cardiopulmonary diseases, liver and/or renal disorders
- Used drugs that could interact with MgSO4 such as nifedipine
- Preoperative body temperature less than 36oC or more than 37.5oC
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium sulfateIV Magnesium sulphate 30 mg/kg, labeled as "research drug" for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression. | Drug | Group M |
| MeperidineIV Meperidine 0.5 mg/kg, labeled as "research drug" for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression. | Drug | Group P |
Primary outcome
Drug effectiveness
Time frame: 120 minutes
Drugs were considered effective if they could prevent the incidence of 3rd or 4th degree shivering
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2021.
- Individual participant dataSharing planned: No
Related trials for Shivering
Not yet recruitingPhase 4
Two Doses of IV Magnesium Sulfate for Prevention of Post-Spinal Shivering
Post Spinal Anesthesia Shivering
Not yet recruiting
Effect of Laryngeal Mask Airway vs Endotracheal Tube on Hypothermia in Laparoscopic Hernia Surgery
Perioperative Hypothermia, Hernia, Inguinal
Not yet recruiting
Resistive Versus Forced-Air Warming for Prevention of Perioperative Hypothermia
Perioperative Hypothermia, Inadvertent Perioperative Hypothermia
Recruiting
Effect Of Acupressure On Hypothermıa And Shıverıng After Cesarean Sectıon
Hypothermia, Shivering
Not yet recruitingPhase 4
Optimizing the Paracetamol Dose for Prevention of Post-Spinal Shivering in Lower Limb Orthopedic Surgeries
Shivering, Postoperative Shivering
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Magnesium sulfate and Meperidine in people with Shivering, run by AnestesiaR at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Drug effectiveness (time frame: 120 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2021.